Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex Pharmaceuticals Down Over 8%, Worst Performer in The S&P 500 and Nasdaq 100 So Far Today -- Data Talk

06/11/2021 | 10:53am EDT

Vertex Pharmaceuticals Incorporated (VRTX) is currently at $198.12, down $18.65 or 8.6%

-- Would be lowest close since Nov. 7, 2019, when it closed at $195.83

-- On pace for largest percent decrease since Oct. 15, 2020, when it fell 20.7%

-- Snaps a three day winning streak

-- Down 5.04% month-to-date

-- Down 16.17% year-to-date

-- Down 34.63% from its all-time closing high of $303.10 on July 20, 2020

-- Down 26.23% from 52 weeks ago (June 12, 2020), when it closed at $268.56

-- Down 34.63% from its 52-week closing high of $303.10 on July 20, 2020

-- Would be a new 52-week closing low

-- Traded as low as $193.00; lowest intraday level since Oct. 28, 2019, when it hit $192.32

-- Down 10.97% at today's intraday low; largest intraday percent decrease since Oct. 15, 2020, when it fell as much as 21.47%

-- Worst performer in the S&P 500 today

-- Worst performer in the Nasdaq 100 today

-- Third most active stock in the Nasdaq 100 today

All data as of 10:32:45 AM

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

06-11-21 1052ET

All news about VERTEX PHARMACEUTICALS
06/24VERTEX PHARMACEUTICALS INC / MA  : Other Events (form 8-K)
AQ
06/21VERTEX PHARMACEUTICALS  : Health Canada Grants Marketing Authorization for TRIKA..
AQ
06/18VERTEX PHARMACEUTICALS  : Gets Marketing Nod for Cystic Fibrosis Drug Trikafta i..
MT
06/18VERTEX PHARMACEUTICALS  : Health Canada Grants Marketing Authorization for TRIKA..
BU
06/14VERTEX PHARMACEUTICALS  : SVB Leerink Adjusts Vertex Pharmaceuticals' Price Targ..
MT
06/14VERTEX PHARMACEUTICALS  : Truist Securities Adjusts Price Target on Vertex Pharm..
MT
06/14VERTEX PHARMACEUTICALS  : and CRISPR Therapeutics Present New Data in 22 Patient..
AQ
06/14VERTEX PHARMACEUTICALS  : Piper Sandler Adjusts Price Target on Vertex Pharmaceu..
MT
06/11AFTER HOURS WATCH LIST SCORECARD : Pgen, tyme, vrtx
MT
06/11Vertex, Incyte fall; Precigen, Magnachip rise
AQ
More news
Financials (USD)
Sales 2021 6 996 M - -
Net income 2021 1 882 M - -
Net cash 2021 8 136 M - -
P/E ratio 2021 25,9x
Yield 2021 -
Capitalization 49 687 M 49 687 M -
EV / Sales 2021 5,94x
EV / Sales 2022 5,02x
Nbr of Employees 3 400
Free-Float 99,9%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 191,94 $
Average target price 261,78 $
Spread / Average Target 36,4%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS-18.79%49 687
GILEAD SCIENCES, INC.15.31%84 256
WUXI APPTEC CO., LTD.35.04%68 803
REGENERON PHARMACEUTICALS12.70%56 381
BIONTECH SE179.43%55 016
BEIGENE, LTD.36.35%32 607